What is Bionano Genomics, Inc.'s Shariah compliance score?

Bionano Genomics, Inc.'s (BNGO) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Bionano Genomics, Inc. pass AAOIFI screening?

Bionano Genomics, Inc. (BNGO) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BNGO: 48.2%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Bionano Genomics, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Bionano Genomics, Inc. (BNGO) using the latest financial data.

Where can I screen Bionano Genomics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Bionano Genomics, Inc. (BNGO) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BNGO's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

BNGO: Is Bionano Genomics, Inc. Halal?

Bionano Genomics, Inc.

NASDAQHealthcareUS

$1.25

+2.46%

Market Cap: 14.3M

Compliance Status

Not Halal

Screened on Aug 26, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Bionano Genomics, Inc. (BNGO) halal? Not Halal. Based on AAOIFI screening, Bionano Genomics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Over the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

48.2% of 30.0% limit

What this means for you

Most scholars advise not holding BNGO

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Bionano Genomics, Inc.

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Sector: Healthcare · Industry: Medical - Instruments & Supplies

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 26, 2026

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

RGCA+

Regencell Bioscience Holdings Limited

$5.02

-4.92%

0001.KLA+

Supercomnet Technologies Bhd

$0.52

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

-0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.38

-0.01%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track BNGO and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Bionano Genomics, Inc. (BNGO) halal to invest in?

Bionano Genomics, Inc. (BNGO) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Bionano Genomics, Inc. get a F compliance rating?

Bionano Genomics, Inc. (BNGO) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 48.2% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Bionano Genomics, Inc.'s Shariah verdict?

Bionano Genomics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Bionano Genomics, Inc. re-screened for Shariah compliance?

Bionano Genomics, Inc. (BNGO) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 26, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.